Apyx Medical

Apyx Medical

Apyx Medical manufactures and markets the Renuvion helium-plasma platform, which physicians use for cutting, coagulation, and skin contraction. The company operates as a commercial-stage medical device firm rather than a traditional investment vehicle — its assets are its intellectual property, manufacturing capacity, and direct sales relationships with cosmetic surgeons and hospital systems. Revenue derives from handpiece and generator sales plus recurring disposable consumables, with a historical geographic concentration in the United States. The firm's go-to-market strategy targets plastic surgeons, dermatologists, and ear-nose-and-throat specialists. Renuvion's primary aesthetic application is as an alternative to invasive body-contouring procedures. The platform received FDA 510(k) clearance for general soft tissue cutting and coagulation; more specific cosmetic claims have required ongoing clinical dossier development. Stock ticker is APYX on Nasdaq, following a corporate rebrand from Bovie Medical in 2019 that aligned the corporate identity with the flagship technology. The company underwent a significant structural shift in 2018, divesting its legacy electrosurgical OEM business to Specialty Surgical Instrumentation to focus exclusively on the higher-growth cosmetic surgery segment. This transaction transformed the firm from a diversified manufacturer into a pure-play aesthetics company reporting a single operating segment. Apyx's structural differentiator lies in its razor-and-blades revenue model within an elective-procedure market: generators require capital outlay, but handpiece disposables create recurring surgeon demand. The firm faces direct competition from AbbVie's CoolSculpting and Cynosure's radiofrequency devices, but helium plasma offers a differentiated mechanism of action by combining ionized helium with radiofrequency energy to achieve tissue effects at lower temperatures than conventional electrocautery.